STING Agonist Induced Sjögren’s Syndrome Mouse Model
The STING agonist DMXAA induced Sjögren’s Syndrome model involves the activation of the stimulator of the interferon gene (STING) pathway to mimic the early symptoms of disease manifestation.
Fig.1 STING Agonist induced mouse Sjögren’s Syndrome model
The STING agonist DMXAA induced Sjögren’ s Syndrome model strategy is shown in Fig.1A. The salivary flow rate of B6 mice in the DMXAA treated group decreased following DMXAA administration for 28 days. (Fig.1B). The level of anti-dsANA and anti-dsDNA in the serum increased in model group (Fig.1C). The mRNA level of mIFN-β, mIL6, mTNF-αand mMx1 in modeling group mice saliva gland tissue significantly increased (Fig.1D). The percentage of neutrophils,monocytes, eosinophils and NK cells increased in blood (Top) and spleen (Bottom) of modeling group.